The Food and Drug Administration approved Adamas Pharmaceuticals' drug Gocovri to treat dyskinesia, a side effect of a medication prescribed to most Parkinson's disease patients, reports Reuters.
Here are three things to know.
- The Parkinson's drug levodopa can cause dyskinesia, or uncontrolled, involuntary movement.
- Gocovri is a once-daily drug intended to control levodopa-induced dyskinesia. The drugs main ingredient, amantadine, has been on the market for several decades as an antiviral drug.
- Adamas Pharmaceuticals expects the drug to be available in the fourth quarter of this year and formally launch in January 2018.